Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Momelotinib's unique polypharmacology supports indication expansion beyond myelofibrosis

View Full Paper
Ask AI
Bookmark
Share

Authors

MAMary A. AntonysamyHTHoang TranAMAnthony Mazurek

Discussion

Loading...

Member takes

Overview

Observational analysis shows momelotinib improves anemia and reduces blood transfusions in myelofibrosis, indicating its potential in pro-inflammatory diseases.

Key Points

  • Momelotinib improves anemia in myelofibrosis, and reduces the need for blood transfusions.
  • In preclinical assays, it demonstrated significant inhibition of pro-inflammatory cytokines, including IL-1β.
  • Assessment using chemoproteomic assays confirmed its unique kinase selectivity profile, targeting ACVR1 and others.
  • These findings highlight momelotinib's polypharmacology, advocating for its use in broader therapeutic areas beyond myelofibrosis.

Cite This Study

Antonysamy et al. (2025) studied this question.

synapsesocial.com/papers/69362f5d4fa91c937236dc21https://doi.org/10.1182/blood-2025-7853
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of drug combinations with momelotinib to improve myelofibrosis outcomes2025
  2. 2Efficacy and Safety of Momelotinib in Myelofibrosis: A Systematic Review and Meta-Analysis With a Focus on Anemia Outcomes.2025 · 2 citations
  3. 3Efficacy of Momelotinib in Myelofibrosis Patients: Results From a Multicenter Study2025 · 2 citations
  4. 4Enhanced antileukemic activity of momelotinib in combination with venetoclax and azacitidine compared to gilteritinib-based combination2025
  5. 5Momelotinib inhibition of JAK/STAT in a mouse JAKV617F myelofibrosis model showed concurrent activation of p-ERK and p-AKT which was reversed by combination therapy using LP-182, a novel MEK/PI3K/mTOR inhibitor2025